2024-09-07 - Analysis Report
##  ABBV Stock Analysis Report

**Company Overview:** AbbVie Inc. (ABBV) is a global pharmaceutical company focused on developing and delivering innovative therapies in various areas, including immunology, oncology, neurology, and eye care.

**Performance Analysis:**

**1. Return vs. S&P 500:**

* ABBV's cumulative return is **106.38%**, significantly outperforming the S&P 500 (VOO) with a cumulative return of **89.66%**.
* The current performance gap between ABBV and VOO is **16.72%**, which falls within the historical range of **-37.86% to 45.56%**.
* The relative divergence is **65.53%**, indicating ABBV's performance is at the higher end of its historical performance range compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** 196.31
* **5-day Moving Average:** 196.05
* **20-day Moving Average:** 193.17
* **60-day Moving Average:** 179.48

ABBV's price is currently above all its moving averages, suggesting a potential upward trend.

**3. Technical Indicators:**

* **RSI:** 74.27 (Overbought)
* **PPO:** -0.36 (Weakly Bearish)
* **Delta_Previous_Relative_Divergence:** -3.27 (Short-term Downtrend)
* **Expected Return:** 16.29% (Max 5-year expected return)

The high RSI indicates the stock is overbought, while the weak PPO suggests a potential slowdown in the upward trend. The negative delta in relative divergence confirms a short-term downward trend. However, the high expected return suggests a potential for future growth.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

ABBV has consistently exceeded earnings expectations in the past 5 quarters. The latest earnings report shows EPS of 2.65, surpassing the expected 2.57. This positive earnings trend indicates strong underlying business performance and justifies the positive outlook for future growth.

**5. Overall Analysis:**

ABBV shows strong performance compared to the market benchmark, with a high cumulative return and consistent outperformance over the S&P 500. The recent price movement and technical indicators suggest potential short-term pullback, but the long-term outlook remains positive. The company's strong earnings and exceeding expectations further reinforce a bullish sentiment for ABBV. 

**6. Conclusion:**

Despite the potential for short-term correction due to overbought conditions, ABBV remains a compelling investment option with its consistent outperformance, strong earnings, and positive future outlook. Further analysis and monitoring of technical indicators and market trends are recommended before any investment decision. 
